Skip to content
Tenfell
Awarded contract
Published 22 Dec 2016

Radium-223 therapy for bone metastasis from prostate cancer

Northampton General Hospital N H S Trust

Key facts

Contract value
£2,200,000
Awarded
24 Nov 2016
Contract starts
22 Dec 2016
Contract ends
03 Sep 2020
Procedure
Other -
Buyer type
Health

Awarded to

SupplierValue
Bayer plc£2,200,000

Description

NGHT has had to publish a VEAT notice for the following therapy: Xofigo (Radium 223) Dose.

The reason for the VEAT notice was due to: "There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years. This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment. This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.

Categories (CPV)

Similar open tenders

About Northampton General Hospital N H S Trust

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.